-+ 0.00%
-+ 0.00%
-+ 0.00%

Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate oncology platform, iopofosine I-131 program

PUBT·08/18/2026 19:24:22
Listen to the news
Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate oncology platform, iopofosine I-131 program
  • Cellectar outlined a Phase 3 confirmatory study for iopofosine I 131 in Waldenström macroglobulinemia, targeting first patient enrolled in 1Q27.
  • Accelerated approval filing targeted for 1H27 using Phase 2b CLOVER-WaM data with Phase 3 initiation and progress.
  • Phase 2b CLOVER-WaM showed statistically significant primary endpoint; evaluable population ORR 83.6%, MRR 61.8%, DCR 98.2%, VGPR/CR 14.5%.
  • Median duration of response 533 days (17.8 months); median progression-free survival 406 days (13.5 months) at December 2025 cutoff.
  • Presentation also highlighted PDC platform expansion, including CLR 125 in Phase 1b/2 TNBC and CLR 225 Actinium-225 pancreatic program listed as Phase 1a/b ready.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief on August 18, 2026, and is solely responsible for the information contained therein.